Translating Precision Biomarkers into Clinical Trials with AI and Digital Pathology

• Advancing translational biomarker discovery by integrating novel assays with AI-driven image analysis to bridge preclinical findings into proof-of-concept clinical testing.
• Leveraging virtual IHC to increase efficiency in clinical trial biomarker evaluation by using H&E-based screening to rapidly identify the most informative biomarkers for PD/MoA studies and patient stratification.
• Confirming and refining biomarkers for clinical use through targeted mIF/IHC validation of the top candidates, enabling the development of robust, trial-ready clinical assays.

Speakers:

Suzanne Coberly

Senior Director - Translational Pathology

Bristol Myers Squibb